Nicholas Ashton
Neuroscientist in Dementia / Banner Health 🇺🇸/ University of Gothenburg 🇸🇪
Articles
-
2 weeks ago |
alz-journals.onlinelibrary.wiley.com | Nicholas Ashton |Andrea L. Benedet |Guglielmo Di Molfetta |Ilaria Pola
1 BACKGROUND Discovery plasma proteomics has long since demonstrated a differential signal in the blood of patients clinically diagnosed with Alzheimer's disease (AD).1, 2 These earlier studies used agnostic methods to discover novel biomarkers—proteomic technologies not predicated on any a priori hypotheses in a case-control approach1, 3-6 but later evolved to an endophenotype design based on pathology; brain atrophy measures,1, 7-9 cerebrospinal fluid (CSF) biomarkers,10 or amyloid beta...
-
1 month ago |
alz-journals.onlinelibrary.wiley.com | Ilaria Pola |Nicholas Ashton |Wagner S. Brum |Nesrine Rahmouni
1 BACKGROUND Alzheimer's disease (AD) is a progressive pathophysiological process characterized by the accumulation of amyloid-β (Aβ) and tau proteins, ultimately leading to neurodegeneration and cognitive decline.1, 2 In this context, neuroinflammation has been suggested as a significant contributor to AD progression.3, 4 Studies in mouse models of Aβ and tau suggest that microglial reactivity may accelerate Aβ plaque deposition and tau spreading, with immune-related alterations observed in...
-
1 month ago |
alz-journals.onlinelibrary.wiley.com | Shorena Janelidze |Nicholas Ashton |Ulrika Nordstrom |Anna Orduña Dolado
1 BACKGROUND Cerebrospinal fluid (CSF) tests for amyloid beta (Aβ) peptides (Aβ42 and Aβ40) and phosphorylated tau-181 (p-tau181) have been used for several decades as biomarkers of Alzheimer's disease (AD).1 More recently, CSF p-tau181/Aβ42 and Aβ42/Aβ40 were approved by the U.S. Food and Drug Administration (FDA) to diagnose AD.2-4 Furthermore, during the past 4 years, blood-based p-tau biomarkers of AD (and p-tau217, in particular) have been applied extensively in research settings and...
-
Feb 26, 2025 |
alz-journals.onlinelibrary.wiley.com | Yara Yakoub |Fernando Gonzalez-Ortiz |Nicholas Ashton |Christine Déry
1 BACKGROUND The core pathological hallmarks that define Alzheimer's disease (AD) are plaque-forming aggregates of amyloid beta (Aβ) and neurofibrillary tangles of hyper-phosphorylated tau (p-tau).
-
Jan 6, 2025 |
thelancet.com | Nicholas Ashton |SUN CITY
In 2014, when eBioMedicine launched its first issue, in vivo biomarkers to detect the hallmarks of Alzheimer’s disease (AD) were entirely restricted to position emission tomography (PET) and cerebrospinal fluid (CSF). There was certainly limited enthusiasm that a comparable determination about AD pathology or neurodegeneration could be made from an easily accessible biofluid such as blood.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 3K
- DMs Open
- Yes
Fluid biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay @AlamarBio @andrealessa https://t.co/PZTKwEjqyW https://t.co/pt6jRTXHEJ
Biomarkers of AD-related #neuroinflammation are missing from our toolbox for patient evaluation and research. This great work by @andrealessa start to see a change in that tide. https://t.co/viPbKNQM44 https://t.co/9HMD6JHV7V
I’m proud to share the first PhD paper of my first (formally) PhD student Ilaria Pola, where we investigated proteins associated with TSPO PET imaging. 🥳 We are now already working on the extension of this work, so stay tuned! 🧠💧🩸 @NicholasAshton @mcgillu
RT @andrealessa: I’m proud to share the first PhD paper of my first (formally) PhD student Ilaria Pola, where we investigated proteins asso…